Novo Holdings
The rounds this investor is named on, who it invests beside, and where it shows up.
The rounds this investor is named on, who it invests beside, and where it shows up.
Named on 25 rounds in the feed, most often at Series A and in Biotech.
Novo Holdings A/S is a holding and investment company.
Investment firmCopenhagen, Denmarknovoholdings.comRounds from 2019-05-30 to 2026-09-29
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Breye Therapeutics A clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases | Series A Verified against 4 of 11 sources | $75.8M | 2026-09-29 | [ LEAD ] |
AnaCardio A clinical-stage biopharmaceutical company developing novel therapies for heart failure | Series B |
| $71.0M |
| 2026-09-29 |
| [ LEAD ] |
Crystalys Therapeutics Crystalystx develops therapeutics specifically for treating gout. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2026-07-22 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Crossover financing Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2026-05-04 | [ PART ] |
Coultreon Biopharma Develop autoimmune disease treatments | Series A Verified against 1 of 5 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $125M | 2026-04-28 | [ LEAD ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $108M | 2026-04-15 | [ PART ] |
Alveus Therapeutics Alveustx specializes in developing next-generation treatments for obesity and metabolic diseases. | Series A ext. Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $197M financing total | 2026-02-24 | [ PART ] |
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series C Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $157M | 2025-10-27 | [ PART ] |
Expedition Therapeutics Expedition Therapeutics develops novel treatments for inflammatory and respiratory diseases, specifically targeting chronic obstructive pulmonary disease (COPD). | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $165M | 2025-10-09 | [ LEAD ] |
Crystalys Therapeutics Crystalystx develops therapeutics specifically for treating gout. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $205M | 2025-09-30 | [ LEAD ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series D Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-07-23 | [ PART ] |
GlycoEra Biologics aimed at precision immunology, targeting and degrading specific proteins associated with autoimmune diseases for improved patient outcomes. | Series B Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $130M | 2025-05-27 | [ LEAD ] |
Glycomine Glycomine develops replacement therapies for rare genetic diseases, particularly focusing on PMM2-CDG treatments. | Series C Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $115M | 2025-04-16 | [ PART ] |
Supira Medical Supira Medical develops a next-generation percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional heart procedures. | Series E Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $120M | 2025-03-26 | [ LEAD ] |
Callio Therapeutics Dual-payload antibody-drug conjugates (ADCs) for cancer treatment. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $187M | 2025-03-03 | [ PART ] |
Windward Bio Windward Bio develops ultra-long-acting monoclonal antibodies for the treatment of serious respiratory and dermatologic diseases, targeting conditions like asthma and COPD. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2025-01-10 | [ LEAD ] |
AvenCell Therapeutics A privately held clinical-stage company developing CAR-T therapies | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $112M | 2024-10-22 | [ LEAD ] |
energyRe An American-led energy company created to develop innovative infrastructure projects that meet rising electricity demand with affordable and reliable energy | Capital package Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $1.2B | 2023-12-04 | [ PART ] |
Terremoto Cutting-edge small-molecule therapies for cancer and other diseases targeted primarily at healthcare providers and researchers. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $175M | 2023-11-02 | [ PART ] |
Hemab Therapeutics Hemab develops targeted therapies for bleeding disorders, focusing on conditions like Glanzmann Thrombasthenia and Von Willebrand Disease. | Series B Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $135M | 2023-02-21 | [ PART ] |
Breye Therapeutics A clinical-stage biopharmaceutical company developing oral therapeutics for the early treatment of retinal diseases | Seed Developing, 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $4.0M | 2022-11-10 | [ LEAD ] |
Noom Noom pairs GLP-1 medication with a personalized program - so it’s not just weight loss, it’s change that lasts. | Series F Verified against 1 of 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $540M | 2021-05-25 | [ PART ] |
Tempus Tempus provides data-driven, AI-enabled solutions for healthcare professionals, particularly in oncology and other medical specialties. | Series D+ Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2020-12-10 | [ PART ] |
Tempus Tempus provides data-driven, AI-enabled solutions for healthcare professionals, particularly in oncology and other medical specialties. | Series D+ Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2020-03-13 | [ PART ] |
Tempus Tempus provides data-driven, AI-enabled solutions for healthcare professionals, particularly in oncology and other medical specialties. | Series D+ Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $200M | 2019-05-30 | [ PART ] |